Screener
Veracyte VCYT Testing revenue — Cost of Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Biopharmaceutical and other revenue | 301 | 3,584 |
| Total revenue | 139,071 | 114,473 |
| Cost of revenue: | ||
| Cost of testing revenue | 33,306 | 28,260 |
| Cost of product revenue | 1,891 | 1,422 |
| Cost of biopharmaceutical and other revenue | 8 | 2,698 |
| Intangible asset amortization - cost of revenue | 2,707 | 2,585 |
| Total cost of revenue | 37,912 | 34,965 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's testing revenue — cost of revenue?
- Veracyte (VCYT) reported testing revenue — cost of revenue of $33.31M in Q1 2026.
- How has Veracyte's testing revenue — cost of revenue changed year-over-year?
- Veracyte's testing revenue — cost of revenue increased by 17.9% year-over-year, from $28.26M to $33.31M.
- What is the long-term trend for Veracyte's testing revenue — cost of revenue?
- Over 4 years (2021 to 2025), Veracyte's testing revenue — cost of revenue has grown at a 21.3% compound annual growth rate (CAGR), from $58.86M to $127.56M.
- What does testing revenue — cost of revenue mean?
- This reflects the direct costs incurred to deliver diagnostic testing services, including materials, labor, and allocated overhead. Monitoring this metric helps assess the direct profitability and operational efficiency of the testing segment.
Ask your AI about Veracyte's testing revenue — cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude